• Hepatera Ltd., of Moscow, a biotech company that is part of Maxwell Biotech Venture Fund's portfolio, said it enrolled the first three patients with chronic hepatitis B virus (HBV) in its Phase Ib/IIa study of Myrcludex B, a drug designed to inhibit the essential HBV receptor on the liver cell surface, preventing the infection of healthy cells and viral spreading in the liver. Results are expected by the end of 2013.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter